Table 1. Patient demographics.
| Parameter/dose level | 320 IU m−2 | 160 IU m−2 | Overall |
|---|---|---|---|
| Case, number | 34 | 37 | 71 |
| Gender | |||
| Male | 30 (88.2%) | 29 (78.4%) | 59 (83.1%) |
| Female | 4 (11.8%) | 8 (21.6%) | 12 (16.9%) |
| Age | |||
| Median | 55 | 56 | 55 |
| Range | 31–82 | 27–80 | 27–82 |
| Karnofsky performance status | |||
| 100 | 5 (14.7%) | 5 (13.5%) | 10 (14.1%) |
| 90 | 21 (61.2%) | 28 (75.7%) | 49 (69.0%) |
| 80 | 8 (23.5%) | 4 (10.8%) | 12 (16.9%) |
| Child–Pugh class | |||
| A | 31 (91.2%) | 34 (91.9%) | 65 (91.6%) |
| B | 3 (8.8%) | 3 (8.1%) | 6 (8.4%) |
| HbsAg | |||
| Positive | 25 (73.5%) | 24 (64.9%) | 49 (69.0%) |
| Negative | 9 (26.5%) | 13 (35.1%) | 22 (31.0%) |
| Anti-HCV antibody | |||
| Positive | 8 (23.5%) | 11 (29.7%) | 19 (26.8%) |
| Negative | 24 (76.5%) | 25 (67.6%) | 51 (71.8%) |
| Unknown | 0 (0.0%) | 1 (2.7%) | 1 (1.4%) |
| Vascular invasion | |||
| Absent | 10 (29.4%) | 22 (59.5%) | 32 (45.1%) |
| Present | 24 (70.6%) | 15 (40.5%) | 39 (54.9%) |
| Extrahepatic metastases | |||
| Absent | 15 (44.1%) | 15 (40.5%) | 30 (42.3%) |
| Present | 19 (55.9%) | 22 (59.5%) | 41 (57.7%) |
| Prior therapy | |||
| Hepatic resection | 11 (32.4%) | 18 (48.6%) | 29 (40.8%) |
| Transcatheter arterial chemoembolization | 21 (61.8%) | 25 (67.6%) | 46 (64.8%) |
| Radiotherapy | 8 (23.5%) | 11 (29.7%) | 19 (26.8%) |
| Systemic therapy | 16 (47.0%) | 15 (40.5%) | 31 (43.6%) |
| Thalidomide alone | 4 (11.8%) | 3 (8.1%) | 7 (9.9%) |
| Chemotherapy with/without thalidomide | 8 (23.5%) | 8 (21.6%) | 16 (22.5%) |
| Anti-angiogenic therapya | 4 (11.8%) | 4 (10.8%) | 8 (11.3%) |
Abbreviation: HbsAg=hepatitis B surface antigen.
a
Including PI88 in 3, sorafenib in 2, sunitinib in 1 and bevacizumab in 2.